BOTHELL, Wash., Aug. 18, 2008 (GLOBE NEWSWIRE) -- Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) announced today that its Board of Directors has set August 19, 2008, as the date of its Special Meeting of Shareholders to vote on the Company's pending merger with OncoGenex Technologies, Inc.
The meeting will start at 9:00 a.m., Pacific Time, and will be held at the Grand Hyatt Seattle, 721 Pine Street, in Seattle, Washington. The voting record date is July 23, 2008.
To access the live webcast of Sonus' Special Shareholders' Meeting, go to the Company's website at www.sonuspharma.com. The webcast can then be accessed under the Investor Relations' section.
Sonus Pharmaceuticals has filed a registration statement containing a proxy statement that was sent to its shareholders and other relevant documents concerning the proposed merger with the U.S. Securities and Exchange Commission (the "SEC"). Investors are able to obtain these documents free of charge at the SEC's web site (http://www.sec.gov) or the Company's web site (www.sonuspharma.com).
About Sonus Pharmaceuticals, Inc.
Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of cancer drugs that are designed to provide better efficacy, safety and tolerability, and ease of use. Sonus moved an oncology product candidate, SN2310, into a Phase 1 clinical trial in September 2006. For additional information on Sonus, including past news releases, please visit www.sonuspharma.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the proposed merger between Sonus and OncoGenex. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, statements of expected synergies, the strength of the combined oncology product pipeline, the timing of clinical trials and development efforts, the results of clinical and pre-clinical studies, the timing of closing, execution of integration plans and management and organizational structure are all forward-looking statements. The potential risks and uncertainties include, among others, the possibility that the merger does not close or that the closing may be delayed, synergies and costs savings will not be achieved or that the companies are unable to successfully execute their integration strategies, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities, risks that the combined company will not be able to maintain listing on NASDAQ, as well as other risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. A more complete discussion of risks and uncertainties that may affect forward-looking statements is included in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2007, and its Quarterly Report on Form 10-Q for the first quarter of 2008. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Sonus. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.